Device Trial Radar · NCT04945824
A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Feb 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2
Actual
Start
Jun 1, 2021
Primary completion
Nov 1, 2022
Study completion Nov 1, 2022
Sponsor
- Lead sponsor
- Ocular Therapeutix, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 30, 2021
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center, bilateral, human factors study designed to evaluate the utilization and safety of a novel intracanalicular insertion device in healthy subjects and to evaluate the concentration of DEXTENZA in tears. Each subject's participation is expected to last for approximately 1 month from the DEXTENZA insertion.
Conditions
- Healthy
Interventions
Dexamethasone OphthalmicDrug
Insertion Device: A handheld mechanical device used by the clinician to dilate the punctum and deliver the DEXTENZA insert into the canaliculus; designed to be single-use and pre-loaded with a single DEXTENZA insert.
DilatorDevice
Intracanalicular Dilator Device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ease of insertion as assessed by Post-Insertion Investigator QuestionnaireTime frame: Assessed at Visit 1 (Day 1)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ocular Therapeutix, Inc.
Sioux Falls, South Dakota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.